NCT06955286 Study on the Incidence of Adrenal Insufficiency After Surgery in Primary Aldosteronism Patients Concurrent With or Without Autonomous Cortisol Secretion
| NCT ID | NCT06955286 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Qifu Li |
| Condition | Primary Aldosteronism |
| Study Type | OBSERVATIONAL |
| Enrollment | 521 participants |
| Start Date | 2025-01-02 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 521 participants in total. It began in 2025-01-02 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the incidence of adrenal insufficiency after surgery in Primary aldosteronism (PA) patients concurrent with or without autonomous cortisol secretion (ACS). To assess the recovery time of postoperative adrenal insufficiency in patients. And to explore the clinical characteristics and predictive indicators of patients requiring postoperative hormone replacement therapy.
Eligibility Criteria
* A confirmed diagnosis of primary aldosteronism or autonomous cortisol secretion; ② Completion of unilateral adrenal surgery; ③ Voluntary participation and obtaining informed consent. (2) Exclusion criteria * Patients with typical clinical manifestations of Cushing's syndrome; * Patients suspected of having bilateral cortisol over-secretion, such as PBMAH or PPNAD; ③ Patients with severe surgical complications, unstable postoperative condition (not due to cortical insufficiency), and difficulty completing the ACTH stimulation test; * History of ACTH allergy; * Patients requiring long-term hormone therapy for other diseases (such as autoimmune diseases); * Severe liver and kidney dysfunction (ALT ≥ 3 times the upper limit of normal; patients undergoing dialysis or with an estimated glomerular filtration rate \< 30 ml/min/m2); ⑦ History of contralateral adrenal surgery; ⑧ Patients with poor compliance who are unable to complete the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06955286 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Primary Aldosteronism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06955286 currently recruiting?
Yes, NCT06955286 is actively recruiting participants. Contact the research team at liqifu@yeah.net for enrollment information.
Where is the NCT06955286 trial being conducted?
This trial is being conducted at Chongqing, China.
Who is sponsoring the NCT06955286 clinical trial?
NCT06955286 is sponsored by Qifu Li. The trial plans to enroll 521 participants.